EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Therapies in Advanced Cholangiocarcinoma

Michael H Storandt iD, Peter C Kurniali, Amit Mahipal, Zhaohui Jin iD

Life · 16.10.2023 · 13 (10) · 2066

DOI: 10.3390/life13102066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 16.10.2023. Verfasst von Michael H Storandt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary tumor resection and liver transplantation are the only curative treatment options for the management of cholangiocarcinoma (CCA). However, for patients with advanced or metastatic disease, palliative systemic therapy remains the only treatment option. The development of targeted therapeutics has begun to shift the treatment paradigm in CCA. Targets of interest in CCA include mutated isocitrate dehydrogenase-1 (mIDH-1), human epidermal growth factor receptor 2 (HER2) overexpression/amplification, and fibroblast growth factor receptor 2 (FGFR2) fusion, in addition to less frequently observed targets such as BRAF V600E, deficient mismatch repair/high microsatellite instability (dMMR/MSI-H), and high tumor mutation burden (TMB-H). These targets are observed in varying frequency among patients with intrahepatic CCA and extrahepatic CCA. Multiple novel therapies have been developed to exploit each of these targets, with some having received United States Food and Drug Administration approval for use in the second-line setting. In the current review, we discuss targets of interest in CCA and summarize current evidence evaluating available therapies directed at these targets.

Schlagwörter

Stichwörter der Autor:innen

cholangiocarcinomasystemic therapytargeted therapy

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Hematology/Medical Oncology, Sanford Cancer Center, Bismarck, ND 58501, USA.
  • Department of Internal Medicine, Division of Hematology/Oncology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203, USA.
  • Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, USA.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Michael H Storandt, Zhaohui Jin

Zitieren

APA

Storandt, M. H., Kurniali, P. C., Mahipal, A., & Jin, Z. (2023). Targeted Therapies in Advanced Cholangiocarcinoma. Life, 13(10), 2066. https://doi.org/10.3390/life13102066

Vancouver

Storandt MH, Kurniali PC, Mahipal A, Jin Z. Targeted Therapies in Advanced Cholangiocarcinoma. Life. 2023;13(10):2066. doi:10.3390/life13102066

BibTeX
@article{Storandt2023,
  author = {Storandt, Michael H and Kurniali, Peter C and Mahipal, Amit and Jin, Zhaohui},
  title = {Targeted Therapies in Advanced Cholangiocarcinoma},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {2066},
  doi = {10.3390/life13102066}
}
Kostenlos starten →